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Abstract
Background: Colorectal cancer is the major cause of cancer mortality, despite development of therapeutic
strategies. The novel marker tumor necrosis factor receptor-associated protein 1 (TRAP1) is a mitochondrial heat
shock protein that has been related to drug resistance and protection from apoptosis in colorectal cancer. This
study aims to delineate the clinicopathologic significance of TRAP1 expression in colorectal cancer.
Methods: Seven-hundred and fourteen FFPE tissues were collected from colorectal cancer patients who underwent
surgery from February 2002 to July 2011 at Dong-A University Medical Center, Busan, South Korea. We performed
TRAP1 immunohistochemistry using tissue microarray, and divided into two groups, TRAP1 high expression group
and low expression group. Statistical analysis was utilized to evaluate the association of TRAP1 with
clinicopathologic characteristics and disease-specific survival of patients.
Results: High TRAP1 expression was observed in 564 cases (79%) and low expression was 150 cases (21%). TRAP1
expression was significantly increased in colorectal cancer with advanced pathologic T-stage compared with that in
early T-stage (p = 0.008). By univariate survival analysis, high TRAP1 expression was significantly associated with worse
disease-specific survival (p = 0.01). But, TRAP1 expression was marginally associated with lymph node involvement and
tumor differentiation (p = 0.085, p = 0.082, respectively). Multivariate analysis indicated that TRAP1 expression (hazard
ratio, 1.947; 95% CI, 1.270 to 2.984; p = 0.002), and pathologic T stage (hazard ratio, 3.190; 95% CI, 1.275 to 7.983; p = 0.
013) were independent prognostic factors for colorectal adenocarcinomas.
Conclusions: Here, we found that overexpression of TRAP1 might contribute to tumor cell local invasion of colorectal
cancer. The association between TRAP1 overexpression and worse disease-specific survival also suggested that TRAP1
protein expression might have oncogenic role. Consequently, our data demonstrated that TRAP1 expression was a
good prognostic biomarker for depth of invasion and disease-specific survival in colorectal cancer.
Keywords: TRAP1 (tumor necrosis factor receptor-associated protein 1), Colorectal cancer, Local invasion, Disease-
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Background
Colorectal cancer is one of the most commonly diagnosed
cancers along with breast, lung and bronchus cancers in
men and women. The incidence of colorectal cancer rap-
idly declines with increased screening and removal of pre-
cancerous lesions by colonoscopy. Nevertheless, in 2016,
colorectal cancer is still a major cause of cancer death in
men and women [1]. There are no treatment options for
advanced colorectal cancer patients after all approved
standard therapies, but many patients maintain a good
performance status and could be candidates for further
targeted therapy [2].
Tumor necrosis factor receptor associated protein 1
(TRAP1) is a molecular chaperone of the 90 kDa heat
shock protein (HSP90) family, and is mostly localized to
the mitochondrial matrix. TRAP1 was first identified as
a protein interacting with the intracellular domain of the
type 1 TNF receptor. Further sequence analysis revealed
that TRAP1 was identical to heat shock protein 75
(HSP75) [3]. Biologically, TRAP1 modulates the perme-
ability transition pore of mitochondrial inner membrane,
and protects the mitochondrial structure from excessive
reactive oxygen species (ROS) induced cell death, such
as in Parkinson’s disease and cancers [4, 5].
TRAP1 is undetectable or expressed at very low levels
in normal tissue, but is up-regulated in various human
malignancies, including ovarian carcinoma cell lines [6],
colorectal carcinomas [7], high-grade prostatic intrae-
pithelial neoplasia, Gleason grades three through five
prostatic adenocarcinomas [8], and kidney cancer [9].
Recent studies show that TRAP1 is associated with posi-
tive lymph node metastasis [10], multi-drug resistance
[7], and shorter median overall survival [11] in colorectal
cancer. But there are still limited researches about
relationship between TRAP1 expression and pathologic
parameters in colorectal cancers.
In this study, we delineate clinicopathologic significance
of TRAP1 using a large number of formalin-fixed
paraffin-embedded (FFPE) specimens of colorectal cancers
to investigate its potential as a biomarker, and analyze the
prognostic significance of the TRAP1 status.
Methods
Patients and samples
Seven-hundred and fourteen FFPE tissues were collected
from colorectal cancer patients, who underwent surgery
from February 2002 to July 2011 at Dong-A University
Medical Center, Busan, South Korea. Eligible samples were
obtained from colorectal cancers without preoperative
chemotherapy or radiotherapy history. Excluded were
histologic types other than primary colorectal adenocar-
cinoma, and patients with co-existing malignancy.
Tissue microarrays (TMAs) were constructed from rep-
resentative tissue from FFPE samples. All the pathologic
slides were reviewed independently by two pathologists,
and the histological type, location, tumor differentiation,
depth of invasion, lymph node metastasis, and lymphovas-
cular invasion were reevaluated. Clinical stage was re-
determined according to the 7th edition of the American
Joint Committee on Cancer TNM staging system [12].
Other clinicopathological data including age, sex, distant
metastasis and survival data were obtained from medical
records. Survival observation time was the time interval
between surgery and the last contact (death due to colo-
rectal carcinoma or last follow-up). Patients without
recurrence or cancer progression were censored at the
time of the last follow-up.
This study was approved by the Institutional Review
Board (IRB) at Dong-A University Medical Center (DAMC
IRB approval No.15-141). Written informed consent was
obtained from all of the patients. All specimens were han-
dled and made anonymous according to the ethical and
legal standards.
Immunohistochemistry
Sections from TMA blocks were transferred onto poly-
L-lysine-coated glass slides. Sections from formalin-fixed
paraffin-embedded blocks were 4 μm in thickness.
Immunohistochemistry was performed using a Ventana
BenchMark XT automated stainer (Ventana Medical
Systems, Tucson, AZ, USA) according to the protocol
with Endogenous Biotin Blocking Kits (Ventana Medical
Systems). The fully automated processing of bar code-
labeled slides included deparaffinization, and antigen
retrieval techniques in EDTA buffer pH 8, and primary
antibody incubation using the TRAP1 antibody (mono-
clonal mouse, Cat 612345, BD BioSciences, San Jose,
CA, USA) at a titer of 1:100. Subsequent reactions with
secondary antibody and visualization were achieved with
DAB (UltraView Universal DAB Detection kit; Ventana
Medical Systems). Formalin fixed, paraffin-embedded
human endometrial tissue (endometrial glandular cells
are positive) was used a positive control according to
antibody manufacturer’s instruction. These sections were
also counterstained with hematoxylin.
All TMA slides were evaluated independently by two
pathologists using light microscopy in a double-blinded
manner. Discordant cases were re-evaluated on a multi-
headed microscope to achieve a consensus. TRAP1 ex-
pression was evaluated for each tissue sample by calculat-
ing a total immunohistochemistry score as the product of
a proportion and intensity score [13]. The proportion
score described the estimated fraction of positively stained
tumor cells (0 = none; 1 = 1 ~ 25%; 2 = 26 ~ 50%; 3 = 51 ~
75%; 4 = 76 ~ 100%). The intensity score represented the
estimated staining intensity (0, negative; 1, weak; 2, mod-
erate; 3, strong) of the samples. TRAP1 expression was
evaluated for each tissue sample by calculating a final
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immunohistochemistry score as the product of the propor-
tion score and the intensity score. The final immunohisto-
chemistry score ranged from 0 to 12. The high-TRAP1
expression group was arbitrarily defined as a total score ≥ 6,
while the low-TRAP1 expression group was considered as
a total score < 6.
Statistical analysis
The following clinicopathologic factors were examed: sex,
age, tumor size, tumor differentiation, pathologic T, N, and
M stage, pathologic TNM stage, lymphovascular invasion,
and TRAP1 expression. Statistical analyses were conducted
using the statistical software SPSS 18.0 for Windows (SPSS
Inc., Chicago, IL, USA). The chi-square test was used to as-
sess TRAP1 expression with respect to clinicopathologic
parameters. The survival curves of the patients were deter-
mined using the Kaplan-Meier method, and the log-rank
test. Cox’s proportional hazard model was used for statis-
tical evaluations. Statistical significance was considered
when probability(p)-value was less than 0.05.
Results
Clinicopathologic characteristics
This study included 714 colorectal adenocarcinoma pa-
tients representing 409 men and 305 women. The median
age at diagnosis was 62 years (range, 22 to 87 years). The
primary tumor locations included 456 (63.9%) in colon, and
258 (36.1%) in rectum. Histologically, 399 tumors (55.9%)
were classified as well-differentiated adenocarcinoma, 270
(37.8%) as moderate-differentiated, 22 (3.1%) as poorly-
differentiated, and 23 (3.2%) as mucinous carcinoma.
Pathological T stage consisted of pTis for 5 tumors (0.7%),
pT1 for 22 (3.1%), pT2 for 85 (11.9%), pT3 for 574 (80.4%),
pT4a for 13 (1.8%), and pT4b for 15 (2.1%). Patients num-
bering at 164 (23%) had lymphovascular invasion, 306
(42.9%) had lymph node metastasis, and 43 (6%) had dis-
tant metastasis at the time of surgery, respectively. Details
of clinicopathologic factors are indicated in Table 1.
Association between TRAP1 expression and
clinicopathologic factors
TMAs containing tissue from 714 colorectal adenocar-
cinomas were stained with anti-TRAP1 antibody, and
the intensity of TRAP1 expression varied from weak to
strong (Fig. 1b: weak, c: moderate, d: strong positive
staining). As presented in Fig. 1, TRAP1 showed no
staining or had very low expression level in normal
colon tissue (Fig. 1a). In colorectal adenocarcinomas,
high-TRAP1 expression was observed in 564 patients
(79%) and 150 patients (21%) showed low-TRAP1 ex-
pression. Examples of high- and low-TRAP1 expressions
are shown in Fig. 2. We evaluated the correlation
between TRAP1 expression and various clinicopatho-
logic factors to assess the diagnostic and prognostic
significance of TRAP1. Chi-square test was used to as-
sess TRAP1 expression with respect to clinicopathologic
parameters. The results revealed that the pathologic T
stage had a statistically positive correlation with TRAP1
expression (p = 0.008). In addition, worse tumor differ-
entiation and increasing pathologic N stage were mar-
ginally associated with TRAP1 expression (p = 0.085,
0.082, respectively), but they were not statistically signifi-
cant. Also, there were no significant associations
between TRAP1 expression and other clinicopathologic
factors of sex, age, tumor size, pathologic M, TNM stage,
and lymphovascular invasion (p > 0.05, Table 1).
Survival according to TRAP1 expression
The median follow-up period of the 714 patients was
64 months (range, 1 to 161 months). Among these 714
patients, 401 were followed-up for more than
60 months. For patients, 60 (8.4%) died from colorectal
adenocarcinomas for a follow-up period. Among the
dead, five of 150 were low-TRAP1 expressers and 55 of
564 belonged to the high-TRAP1 expression group. In
addition, six patients died from pneumonia and one pa-
tient died from a car accident during the follow-up
period. However, they were not included in the number
of deaths for survival analysis. Kaplan-Meier survival
analysis showed that patients with high-TRAP1 expres-
sion had significantly shorter disease-specific survival
than those with low-TRAP1 expression (p = 0.01, Fig. 3).
Further multivariate analysis was performed using Cox
regression model to determine independent prognostic
factors for colorectal adenocarcinomas. Relevant clini-
copathologic factors including sex, age, tumor size,
tumor differentiation, pathologic T, N, and M stage,
pathologic TNM stage, lymphovascular invasion, and
TRAP1 expression were analyzed in the Cox univariate
model. Only those factors with a p value <0.01, patho-
logic T stage and TRAP1 expression, were included in
the multivariate model. Cox proportional hazard
regression analysis indicated that TRAP1 expression
(hazard ratio, 1.947; 95% CI, 1.270 to 2.984; p = 0.002),
and pathologic T stage (hazard ratio, 3.190; 95% CI,
1.275 to 7.983; p = 0.013) were independent prognostic
factors for colorectal adenocarcinomas (Table 2).
Discussion
It is generally accepted that human malignant tumors
develop by genetic alterations and are also composed of
heterogeneous population of cells. Previous studies have
shown that colorectal cancer is also a genetically hetero-
geneous and complicated disease [14]. Numerous thera-
peutic regimens including target therapies for colorectal
carcinomas have been proposed, but with all the cur-
rently approved standard therapies, the disease is still
progressive for the majority of patients.
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Recently, several investigations have shown that TRAP1
is a significant factor related to metastasis and prognosis
in colorectal cancers. Gao et al. found that TRAP1 was
significantly up-regulated in primary colorectal cancers
with lymph node metastasis compared with lymph node
negative ones [10]. Costantino et al. identified that TRAP1
overexpression lead to 5-fluorouracil-, oxaliplatin- and
irinotecan-resistant phenotypes in neoplastic cells [7].
Han et al. demonstrated that the median overall survival
was significantly increased in patients negative for TRAP1
than those positive for TRAP1 [11]. Despite these find-
ings, investigations at a large scale from human colorectal
tissues have been limited to evaluate the relationships be-
tween TRAP1 expression and colorectal cancers with vari-
ous clinicopathologic parameters.
This study showed that the pathologic T stage had a
statistically positive correlation with TRAP1 expression.
In the view of this finding, it seems reasonable to regard
that TRAP1 expression contributes to local cancer inva-
sion. As far as we know, this is the first study to evaluate
the relationship between TRAP1 expression and local
cancer invasion. From these findings, we suggest that
TRAP1 enables tumor cells to invade stromal tissue by
epithelial-mesenchymal transition (EMT). As TRAP1’s
full name, tumor necrosis factor receptor-associated pro-
tein 1 implies [9], TNF-α promotes tumor invasion via
induction of matrix metalloproteinases, and finally mod-
ulates EMT in a model of colorectal cancer [15]. In
addition, TRAP1 inhibits the enzymatic activity of suc-
cinate dehydrogenase (SDH), and SDH inhibition leads
to succinate-dependent hypoxia-inducible factor 1-alpha
(HIF1-a) stabilization [16]. HIF1 stabilization contributes
to neoplastic processes by EMT [17], and EMT plays a
critical role in migration of tumor cells from the primary
site into stromal tissue [18]. The precise pathologic
mechanisms for TRAP1 in promoting cancer invasion
are still not fully understood and many questions remain
to be answered. But TRAP1 seems to be one of the crit-
ical players in biologic processes of tumor invasion in
colorectal cancer.
In this study, an increasing pathologic N stage was mar-
ginally associated with TRAP1 expression. In addition, it is
known that TRAP1 expression is significantly associated




Number TRAP1 expression p value
Lowa (n = 150) Highb (n = 564)
Sex
Male 409 90 319 0.107
Female 305 60 245
Age (year)
≤ 60 297 67 230 0.391
> 60 417 83 334
Tumor Size (cm)
≤ 5 342 64 278 0.149
> 5 372 86 286
Tumor differentiation
Well 399 78 321 0.085
Moderate 270 56 214
Poorly 22 7 15
Mucinous 23 9 14
Pathologic T stage
pTis 5 4 1 0.008
pT1 22 5 17
pT2 85 12 73
pT3 574 120 454
pT4a 13 5 8
pT4b 15 4 11
Pathologic N stage
pN0 408 84 324 0.101
pN1a 98 16 82
pN1b 92 19 73
pN1c 3 1 2
pN2a 60 21 39
pN2b 53 9 44
Pathologic M stage
pM0 671 139 532 0.280
pM1a 24 8 16
pM1b 19 3 16
pTNM stage
0 6 4 2 0.082
I 90 15 75
llA 293 59 234
llB 2 1 1
llC 4 0 4
lllA 14 1 13
lllB 211 46 165
lllC 50 13 37
IVA 25 8 17
Table 1 Relationship between TRAP1 expression and
clinicopathologic factors (Continued)
IVB 19 3 16
Lymphovascular invasion
No 550 111 439 0.321
Yes 164 39 125
atotal score < 6
btotal score ≥ 6
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with lymph node metastasis in colorectal cancers [10],
prostatic cancers [8], and esophageal squamous cell car-
cinomas [19]. These findings are in disagreement with
those of Kubota et al. who recently reported that TRAP1
regulates cell adhesion by modulation of N-cadherin ex-
pression in a neuronal cell line [20]. The aforementioned
study showed that the cell scattering phenotype in the
TRAP1 knockdown cells could be mainly attributed to
impaired expression of cell adhesion molecules including
N-cadherin, which is regulated by TRAP1 transcription.
In our opinion, the two different results may be due to the
different microenvironments in the models studied.
Fig. 1 Intensity score of TRAP1 expression a Negative or very low expression of TRAP1 in normal colon b-d Various TRAP1 expression levels in
colorectal adenocarcinomas b weak c intermediate d strong positive stainings
Fig. 2 Results of TRAP1 expression a-b Low-TRAP1 expression c d High-TRAP1 expression
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Tumor hypoxia can be found in almost every solid tumor,
and gene expression along with associated biological func-
tion can alter according to circumstances such as stressful
tumor microenvironment [21].
In future sudies, expressions of TRAP1 in different
parts of the same tumor, especially in the front of inva-
sion where it has contact with the microenvironment,
need to be determined. Such study will help us elucidate
the relationship between TRAP1 expression and the
tumor microenvironment.
In this study, tumor differentiation showed a marginal
positive correlation with TRAP1 expression. This finding is
similar with that of Li et al. who reported a strong correl-
ation with positive TRAP1 staining and the World Health
Organization (WHO) grade [22]. In the present study,
patients with high-TRAP1 expression showed significantly
shorter disease-specific survival than those with low-
TRAP1 expression. This finding is in accord with an earlier
one on colorectal cancer cases treated with oxaliplatin/5-
fluorouracil [11]. Significant positive correlations between
high-TRAP1 expression and poor prognosis were observed
not only in this study but also in other studies. TRAP1
expression levels were also increased in cisplatin-resistant
ovarian carcinoma cell lines [6], colorectal carcinoma cells
resistant to 5-fluorouracil [7], oxaliplatin and irinotecan [7],
and breast carcinoma cells resistant to paclitaxel [23]. In
addition, high -TRAP1 expression level was also associated
with increased risk of disease recurrence in non-small cell
lung cancer [24]. It is reasonable that TRAP1 contributes
to tumor progression based on these results. In a
stressful environment, permeability transition pore of
mitochondrial inner membrane is opened by accumu-
lated ROS, and consequently cells undergo apoptosis
[4]. TRAP1 protects tumor cells from ROS-dependent
permeability transition pore opening through deregu-
lated mitochondrion-restricted kinase signaling [17].
This may be the key mechanism of TRAP1-related
tumor progression.
Our multivariate analysis showed that TRAP1 expression
was useful for predicting the clinical outcome of colorectal
adenocarcinomas. Therefore, TRAP1 expression can be
used as an additional novel prognostic marker of colorectal
adenocarcinomas.
We revealed that up-regulation of TRAP1 might plays a
major role in biological functions. It particularly influenced
colorectal cancer invasion and disease-specific survival.
Until now, only a limited number of studies have delineated
the pathophysiologic functions of TRAP1 and relationships
between TRAP1 and clinicopathologic factors including
histology in human colorectal cancer tissue. Our study
provides new and important information towards
understanding the pathogenesis of colorectal adenocar-
cinomas. Further investigations are required with
respect to discordant views and precise pathophysio-
logic molecular mechanisms.
Table 2 Cox proportional hazard regression analysis in
colorectal adenocarcinoma
Variables Hazard ratio 95% Confidence interval p value
TRAP1 expression 1.947 1.270–2.984 0.002
Pathologic T stage 3.190 1.275–7.983 0.013
Fig. 3 Kaplan-Meier survival analysis of disease-specific survival according to TRAP1 expression
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Conclusion
In conclusion, we clarified the relationship between
TRAP1 expression and clinicopathologic factors, and
evaluated diagnostic and prognostic significance of
TRAP1 as a potential biomarker, using a large number
of human colorectal adenocarcinoma FFPE samples.
To the best of our knowledge, this is the first large
scale study revealing the relationships between TRAP1
expression in surgically resected specimens with various
clinicopathologic factors and long term follow-up re-
cords. Our study showed that TRAP1 was associated
with local invasion in colorectal adenocarcinomas. Our
results firmly indicated that TRAP1 was as a novel inde-
pendent prognostic factor for colorectal adenocarcin-
omas. It has been recently demonstrated that TRAP1 is
responsible for a multi-drug resistant phenotype in hu-
man colorectal carcinoma cells [7]. This information
confers that TRAP1 expression is not only a prognostic
factor but also a predictive factor for colorectal cancer.
Further studies on TRAP1 expression with clinical trial
might contribute to building a new era of personalized
medicine in treatment for colorectal cancer.
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